18 pharmaceutical companies went public in the third quarter, 3 of which have a market value of nearly 100 billion

[market analysis of chinapharma.com] in the third quarter, 18 pharmaceutical companies entered the A-share market As of the close of October 24, only one with a market value of more than 50 billion yuan was Huada gene, with a market value of 64.37 billion yuan Among them, the market value of DASHENLIN is 17.36 billion yuan, and that of Dabo medical treatment is 16.84 billion yuan Market value: 17.36 billion yuan time flies, in a flash, 2017 has passed more than half According to statistics, in the third quarter, a total of 18 pharmaceutical companies successfully landed in a shares Among them, Huada gene, known as "Tencent of gene industry", dashanlin, the fourth listed chain drugstore, and Dabo medical, one of the leading enterprises in the field of orthopedic implant medical consumables in China, have jointly won a market value of nearly 100 billion 18 pharmaceutical companies were listed in the third quarter In the third quarter, a total of 18 pharmaceutical companies landed in the A-share market As of the close of October 24, only one with a market value of more than 50 billion yuan was Huada gene; 5 with a market value of 10-50 billion yuan were dashanlin, Dabo medical, Jinyu medical, Chenxin pharmaceutical and Jianyou; There are 12 companies under 10 billion yuan, including Harbin Sanlian, egg biology, ADE biology and weixinkang According to the data, the stock price of BGI has soared 11 times since its listing, which is more than 100 yuan than that of one of the listed pharmaceutical companies in the third quarter, and its market value is close to 70 billion yuan Currently ranked seventh in the industry, it is expected to achieve a market value of 100 billion in the future The market value of Huada gene is 64.37 billion yuan In July this year, Huada gene officially entered a share Its main business is to provide genomic diagnosis and research services for medical institutions, scientific research institutions, enterprises and institutions through gene detection and other means The main products include basic research and clinical application services for reproductive health, basic scientific research services, basic research and clinical application services for complex diseases, and basic research and clinical application services for drugs In the first half of 2017, BGI signed comprehensive cooperation agreements with a number of hospitals, and signed strategic cooperation agreements with Fuyang City, Shandong Province, Qingdao City, Shandong Province, Tai'an City and other governments, covering non-invasive prenatal gene testing, newborn gene testing, HPV gene testing, rapid detection of pathogenic microorganisms and other projects Cancer gene detection service has stable business cooperation with more than 150 hospitals in China HLA business has established stable business cooperation with more than 110 hospitals and scientific research institutes, 20 bone marrow and cord blood banks at all levels in China, with more than 446000 samples tested The business scope of the company has covered more than 100 countries and regions in the world, including more than 2000 scientific research institutions and 2300 medical institutions in 31 provinces and autonomous regions in China, including more than 300 top three hospitals; more than 3000 overseas medical and scientific research institutions cooperated in Europe, America, Oceania and other regions In addition, BGI has always attached great importance to the research and development of new service categories, with an investment of 70.9509 million yuan in the first half of the year The company conducts a large number of research and development in the fields of genetic deafness, pre pregnancy genetic disease, non-invasive prenatal testing, tumor and other diagnostic services, as well as basic scientific research On October 13, BGI released the performance forecast for the first three quarters, with the expected net profit of 3 million-32 million yuan, a year-on-year increase of 16.69% - 24.47% The performance growth is mainly due to the overall growth trend of various businesses of the company in the first half of the year, and the growth of reproductive health, basic scientific research, complex diseases and drug research and development and other businesses over the same period of last year Market value of No.2 ginseng forest: 17.36 billion yuan Dashanlin has been focusing on the direct chain retail business of Chinese and Western patent medicine, ginseng antler tonic medicine, Chinese herbal pieces, health care products, medical devices and other commodities, especially in the field of ginseng antler tonic medicine, it has formed its own brand-based business characteristics, covering high, middle and low-grade products, and meeting the needs of different consumers It is a large-scale pharmaceutical retail enterprise in China In the first half of the year, the operating revenue was 350.119 million yuan, an increase of 18.65% year on year, and the net profit attributable to the shareholders of the parent company was 248.42 million yuan, an increase of 14.45% year on year The management strategy of DASHENLIN is to take the direct chain stores as the core, and constantly radiate to the surrounding provinces and cities on the basis of in-depth development and consolidation of the South China market As of the first half of 2017, the company has established 2625 direct chain stores and 232 new stores covering Guangdong, Guangxi, Henan, Fujian, Jiangxi, Zhejiang and other provinces In addition to physical stores, actively expand online sales channels Through self built dashanlin online shopping mall and other e-commerce platforms, the online sales ability and customer service level will be improved In the second half of the year, DASHENLIN will strengthen the network distribution of stores near the hospital, speed up the pace of looking for cooperation targets of M & A, and improve the network layout, especially in the areas where there are already distribution points Continue to improve the competitiveness of commodities, continue to optimize the product structure, speed up the sale of products, and quickly introduce market potential varieties In addition, we should actively prepare for the policy of medical reform, build a professional DTP / DTC pharmacy, actively communicate with related pharmacies, and communicate with medical institutions on the construction of prescription circulation No.3 Dabo medical market value: the main business of Dabo medical is the production, R & D and sales of high-value medical consumables, including orthopedic trauma implant consumables, spine implant consumables and neurosurgery implant consumables, accounting for more than 90% of the company's operating revenue After years of technology research and development and accumulation, at present, the product registration certificate of Dabo Medical Co., Ltd has covered about 15400 specifications of various consumables in orthopedic trauma, spine, neurosurgery and other fields It is worth mentioning that Dabo medical has developed and upgraded some common indications and original products in orthopedic field Some R & D projects include: pre filled artificial bone, absorbable interface screw, vitamin E polyethylene lining in hip replacement, HA coated bone needle, thoracolumbar elastic internal fixation system, etc In the future, it is planned to expand the field of medical high value consumables such as craniomaxillofacial surgery, general surgery, minimally invasive surgery and dentistry while increasing the scale and categories of orthopedic products such as artificial joints and sports medicine, which will become an important driving force for the company's future revenue growth Dabo medical expects the operating revenue of 427.7571 million-46.22537 million yuan in the first three quarters, with a year-on-year growth rate of 24% - 34%; the net profit attributable to the parent company is expected to be 204.7189 million-222.6766 million yuan, with a year-on-year growth rate of 14% - 24% Data source: prospectus, company announcement original title: 18 pharmaceutical companies listed in the third quarter, who is the "potential stock" with a market value of 100 billion?